Recent Updates
Recently added Catalysts

Elinzanetant

Phase 3

Vasomotor Symptoms Associated With Menopause | Small molecule | Endocrine |Bayer AG|Last Updated: Jul 9, 2026

Target and mechanism

Molecular targetTACR1, TACR3
Target classAntagonist
ModalitySmall molecule

Also known as Elinzanetant (BAY3427080)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials3
Total Enrollment1,424

FDA Designations

No designations recorded

Clinical trial landscape

Elinzanetant · 16 trials · 8 indications

Phase 3 4Phase 2 2Phase 1 10
NCT05587296A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerVasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
ACTIVE NOT_RECRUITING474 Analytics
NCT05099159A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)Vasomotor Symptoms Associated With Menopause
COMPLETED400 Analytics
NCT05030584A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the MenopauseVasomotor Symptoms Associated With Menopause
COMPLETED628 Analytics
NCT05042362A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseVasomotor Symptoms Associated With Menopause
COMPLETED396 Analytics
PHASE3ACTIVE NOT_RECRUITING
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerUnlock trial analytics
PHASE3COMPLETED
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Vasomotor Symptoms Associated With MenopauseUnlock trial analytics
PHASE3COMPLETED
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With MenopauseUnlock trial analytics
PHASE3COMPLETED
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Vasomotor Symptoms Associated With MenopauseUnlock trial analytics

Study Endpoints

Primary Endpoints

Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
Baseline to Week 4

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)
Baseline to Week 12

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
From baseline to Week 4

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 4, Day 22-28 were used (Day 1 corresponds to start of treatment).

Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
From baseline to Week 12

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 12, Day 78-84 were used (Day 1 corresponds to start of treatment).

Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
From baseline to Week 4

In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing

Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
From baseline to Week 12

In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])
Baseline to Week 12

The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a "sensation of heat without sweating", moderate HF are defined as a "sensation of heat with sweating, but able to continue activity", and severe HF are defined as a "sensation of heat with sweating, causing cessation (stopping) of activity".

Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).
From baseline to Week 4

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 4, Days 22-28 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).
From baseline to Week 12

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 12, Days 78-84 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).
From baseline to Week 4

In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing.

Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).
From baseline to Week 12

In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)
From baseline until week 4

WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.

Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
From baseline to Week 4

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12
From baseline to Week 12

Participants recorded daily in their electronic diary (eDiary) the frequency and severity of hot flushes during the treatment period. The baseline assessment for hot flushes was calculated using the last 7 days (not necessarily consecutive days) with an available data in the evening and/or the morning of the baseline diary completion period. A diary day was comprised of the evening entry of this day and the morning entry of the following day, in that order. Mean daily frequency = Sum of number of hot flushes filled in the diary during the last 7 diary days (with at least one available data in the evening and/or morning) divided by 7. Moderate: Sensation of heat with sweating, but able to continue activity. Severe: Sensation of heat with sweating, causing cessation (stopping) of activity.

Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4
From baseline to Week 4

Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity is graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12
From baseline to Week 12

Participants recorded daily in their eDiary the frequency and severity of hot flushes during the treatment period. Mean weekly severity = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). Severity was graded by the women from 1 to 3 (1 = mild; 2 = moderate; 3 = severe).

Simulated driving performance as measured by SDLP using CRCDS-MiniSim
Approximately 9 hours after last dose

SDLP: standard deviation of lateral position. CRCDS-MiniSim: Cognitive Research Corporation's Driving Simulator-MiniSim.

Number of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs related to elinzanetant
After first application of study intervention until 20 days after last application of study intervention
Cmax of unconjugated and total dabigatran when given without or together with a single oral dose of elinzanetant
Pre-dose and up until 72 hours post-dose of DBG etexilate

Cmax: maximum observed drug concentration in plasma after single dose

AUC of unconjugated and total dabigatran when given without or together with a single oral dose of elinzanetant
Pre-dose and up until 72 hours post-dose of DBG etexilate

AUC(0-tlast) will be the primary endpoint if AUC cannot be determined in all participants. AUC: area under the concentration vs. time curve from zero to infinity after single dose; AUC(0-tlast): area under the concentration vs. time curve from zero to last quantifiable concentration after single dose

Cmax: maximum observed drug concentration in measured matrix after single dose administration
From pre-dose up to 168 hours after first dosing
AUC: area under the concentration vs. time curve from zero to infinity after single dose
From pre-dose up to 168 hours after first dosing

AUC(0-tlast) will be used as the main parameter if AUC cannot be reliably determined

Cmax,md: maximum observed drug concentration in measured matrix after multiple dose administration
From pre-dose up to 180 hours after last dosing
AUC(0-24)md: AUC from time 0 to 24 hours for multiple dosing
From pre-dose up to 180 hours after last dosing
Area under the concentration versus time curve from zero to infinity of elinzanetant after single dose administration (AUC)
0 to 84 hours after first dose on Study Day 1

AUC from time 0 to the last data point greater than lower limit of quantification (LLOQ) (AUC\[0-tlast\]) will be used as a primary parameter, if AUC cannot be determined in all participants.

Maximum observed drug concentration of elinzanetant in plasma after single dose administration (Cmax)
0 to 84 hours after first dose on Study Day 1
Area under the concentration vs. time curve in plasma from zero to infinity (AUCu) (unbound)
Predose up to 120 hours

Measured matrix after a single dose administration.

Maximum observed (unbound) drug concentration (Cmax,u)
Predose up to 120 hours

Maximum observed (unbound) drug concentration (Cmax,u) in measured matrix after a single dose administration.

Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of elinzanetant without concomitant administration of esomeprazole.
Period 1: Predose, Day 1 to Day 8.

(AUC(0-tlast) will be used as main parameter if AUC cannot be calculated.)

Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of elinzanetant without concomitant administration of esomeprazole.
Period 1: Predose, Day 1 to Day 8.
Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of elinzanetant with concomitant administration of esomeprazole.
Period 2: Predose, Day 1 to Day 8.

(AUC(0-tlast) will be used as main parameter if AUC cannot be calculated.)

Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of elinzanetant with concomitant administration of esomeprazole.
Period 2: Predose, Day 1 to Day 8.
AUC of elinzanetant with carbamazepine.
Period 2: Predose, Day 1 to Day 8

AUC: Area under the concentration vs. time curve from zero to infinity after single (first) dose.

AUC of elinzanetant without carbamazepine.
Period 1: Predose, Day 1 to Day 8

AUC: Area under the concentration vs. time curve from zero to infinity after single (first) dose.

Cmax of elinzanetant with carbamazepine.
Period 2: Predose, Day 1 to Day 8

Cmax: Maximum observed drug concentration in measured matrix after single dose administration.

Cmax of elinzanetant without carbamazepine.
Period 1: Predose, Day 1 to Day 8

Cmax: Maximum observed drug concentration in measured matrix after single dose administration.

Number of participants with and severity of treatment-emergent adverse events (TEAEs)
Up to 2 weeks after start of dosing
Maximum plasma concentration (Cmax) of rosuvastatin when given without or together with elinzanetant
Day 1-3, Day 8-16
Area under the concentration versus time curve (AUC) of rosuvastatin when given without or together with elinzanetant
Day 1-3, Day 8-16

Secondary Endpoints

Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).
Baseline to Week 4
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
Baseline to Week 12
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)
Baseline to Week 1
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Elinzanetant (BAY3427080)EXPERIMENTALParticipants will receive 120 mg elinzanetant orally once daily.
PlaceboPLACEBO_COMPARATORParticipants will receive matching placebo orally once daily for 12 weeks, followed by 120 mg elinzanetant orally once daily
Placebo + elinzanetantPLACEBO_COMPARATORParticipants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
Elinzanetant armEXPERIMENTALParticipants will take Elinzanetant
Placebo armPLACEBO_COMPARATORParticipants will take elinzanetant matching placebo
160 mg Elinzanetant (BAY3427080)EXPERIMENTALParticipants received 4x40 mg elinzanetant capsules.
120 mg Elinzanetant (BAY3427080)EXPERIMENTALParticipants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
80 mg Elinzanetant (BAY3427080)EXPERIMENTALParticipants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
40 mg Elinzanetant (BAY3427080)EXPERIMENTALParticipants received one 40 mg elinzanetant capsule and 3 placebo capsules.
Treatment sequences A-C-D-BEXPERIMENTALTreatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Treatment sequences B-D-C-AEXPERIMENTALTreatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Treatment sequences C-B-A-DEXPERIMENTALTreatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Treatment sequences D-A-B-CEXPERIMENTALTreatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).
Part 1 - Dose group 1EXPERIMENTALSingle oral dose of elinzanetant or placebo.
Part 1 - Dose group 2EXPERIMENTALSingle oral dose of elinzanetant or placebo
Part 1 - Dose group 3EXPERIMENTALSingle oral dose of elinzanetant or placebo
Part 1 - Dose group 4EXPERIMENTALSingle oral dose of elinzanetant or placebo
Part 2: Moxifloxacin - PlaceboEXPERIMENTALParticipants of Dose Groups 1 and 4 will receive a single dose of moxifloxacin in Period 1 and a single dose of placebo in Period 2.
Part 2: Placebo - MoxifloxacinEXPERIMENTALParticipants of Dose Groups 1 and 4 will receive a single dose of placebo in Period 1 and a single dose of moxifloxacin in Period 2.
EZN - DBGEXPERIMENTALParticipants will receive a single oral dose of dabigatran (DBG) etexilate in fasted state in Period 1; followed by a single oral dose of elinzanetant (EZN) and DBG etexilate (30 min after EZN) in fasted state in Period 2.
Treatment A-BEXPERIMENTALParticipants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
Treatment B-AEXPERIMENTALParticipants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
Moderate renal impairmentEXPERIMENTALParticipants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m\^2
Severe renal impairmentEXPERIMENTALParticipants with eGFR \< 30 mL/min/ 1.73 m\^2
Normal renal functionEXPERIMENTALParticipants with ≥ 90 mL/min/1.73 m\^2
Period 1EXPERIMENTALA single dose of elinzanetant and an additional IV (microtracer dose) of \[13C5\]BAY 3427080 will be administered.
Period 2EXPERIMENTALOnce daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
Elinzanetant single dose step 1EXPERIMENTALEach participant will receive a single oral dose of elinzanetant or placebo.
Elinzanetant single dose step 2EXPERIMENTALEach participant will receive a single oral dose of elinzanetant or placebo.
Elinzanetant single dose step 3EXPERIMENTALEach participant will receive a single oral dose of elinzanetant or placebo.
Elinzanetant single dose step 4EXPERIMENTALEach participant will receive a single oral dose of elinzanetant or placebo.
Elinzanetant single dose step 6EXPERIMENTALEach participant will receive a single oral dose of elinzanetant or placebo.
Elinzanetant multiple dose step 5EXPERIMENTALEach participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.
Rosuvastatin and/or elinzanetantEXPERIMENTALThe participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.

Interventions

NameTypeDescription
Elinzanetant (BAY3427080)DRUG120 mg elinzanetant orally once daily
PlaceboDRUGMatching placebo orally once daily
ElinzanetantDRUGOral
Placebo to elinzanetantDRUGOral administration
ZopicloneDRUGOral administration
Placebo to zopicloneDRUGOral administration
MoxifloxacinDRUGSingle oral dose of 400 mg moxifloxacin
Dabigatran etexilateDRUGCapsule, oral, single dose
EsomeprazoleDRUGEsomeprazole given orally once daily for 5 days in Period 2.
MidazolamDRUGMidazolam given orally as single dose in Period 1 and in Period 2.
CarbamazepineDRUGCarbamazepine given orally twice daily in Period 2 .
RosuvastatinDRUGSingle doses on Day 1, Day 8, and Day 13
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexFEMALE
Healthy VolunteersNo
Study Sites102

Inclusion Criteria: * Females aged 18 to 70 years of age inclusive, at the time of signing the informed consent. * Women experiencing vasomotor symptoms (VMS) caused by adjuvant endocrine therapy that they are expected to use for the duration of the study * Tamoxifen with or without the use of g...

Countries:AustriaBelgiumCanadaFinlandFranceGermanyHungaryIrelandIsraelItalyKazakhstanPolandPortugalRomaniaSpainUnited KingdomUnited StatesCzechiaNorwayRussiaSlovakiaSwitzerlandUkraineBulgariaDenmarkGreeceNetherlandsChinaJapan
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWJul 9, 2026NCT05587296lastUpdatePostDate: changed
LOWJul 9, 2026NCT05587296lastUpdatePostDate: changed

Frequently asked questions about Elinzanetant

What is Elinzanetant used for?

Elinzanetant is an investigational small molecule being developed for menopause-related conditions, including vasomotor symptoms (hot flashes) associated with menopause, sleep disturbances associated with menopause, and vasomotor symptoms as a sex hormone-dependent disorder in women and men. It is also studied for vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing, hormone-receptor positive breast cancer.

What does Elinzanetant target?

Elinzanetant is a small molecule being developed by Bayer AG. The specific molecular target is not disclosed in the available clinical trial information. The drug is being studied for its effects on vasomotor symptoms and sleep disturbances related to menopause and other hormone-dependent conditions.

Who makes Elinzanetant?

Elinzanetant is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The drug is also known by the code name BAY3427080.

What phase is Elinzanetant in?

Elinzanetant is in Phase 3 clinical development. One Phase 3 trial (NCT05587296) is active but not recruiting, studying the drug for hot flashes caused by anti-cancer therapy in women with hormone-receptor positive breast cancer. Earlier Phase 1 and Phase 2 trials have been completed.

What clinical trials is Elinzanetant in?

Elinzanetant has been studied in multiple clinical trials. A key ongoing trial is NCT05587296, a Phase 3 study in women with hormone-receptor positive breast cancer experiencing hot flashes from anti-cancer therapy. Completed trials include NCT04889287, NCT05351892, and NCT05481528, which evaluated safety, drug interactions, and absorption in healthy volunteers.

Is Elinzanetant the same as BAY3427080?

Yes, Elinzanetant is also known as BAY3427080. Clinical trial records use both names interchangeably to refer to the same investigational drug being developed by Bayer AG for vasomotor symptoms and related menopausal conditions.